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A yeast two-hybrid screen identifies a novel interactor of the TRAPP subunit
sedlin
Sokunthear HuI
Sedlin is implicated in a diverse set of cellular roles that include membrane trafficking
and gene regulation. Mutations in sedlin lead to a skeletal disorder called SEDT.
However, a complete understanding of the function(s) of sedlin remains elusive. Sedlin is
one component of a large heteromeric complex called TRAPP (transport protein particle)
that is involved in membrane traffic between the endoplasmic reticulum and the Golgi.
To begin to characterize the function of sedlin a yeast two-hybrid (Y2H) screen was
performed. This screen identified a novel sedlin interactor called SPATA4. The
interaction was confirmed both in vitro, using an MBP-pulldown assay, and in vivo, using
coimmunoprecipitation. A gel filtration experiment showed that SPATA4 co-fractionates
with the TPvAPP complex, a result that was supported by in vitro work. Since SPATA4
was originally identified as a protein involved in spermatogenesis, the interaction
between TPAPP and SPATA4 may suggest a specialized role for TRAPP and/or TRAPP
isocomplexes in spermatogenesis. Alternatively, SPATA4 may play a previously
unreported role in membrane traffic. A bioinformatic analysis of SPATA4 revealed a
domain found in another potential sedlin-interactor called SPEFl. A portion of this
domain is known to mediate interaction with microtubules. Taken together, the SPATA4-
TRAPP interaction may link the TRAPP vesicle tethering complex to the cytoskeleton
which transports Golgi-destined vesicles.
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1. Introduction
1 . 1 Membrane Trafficking
In every eukaryotic cell a highly regulated and precise system controls the flow of
proteins and lipids to the correct membrane-bound compartment. This important process
is termed membrane trafficking and is essential in maintaining the identity of all
organelles. Within a cell the main mode of trafficking is vesicular transport. In the latter
case cargo is loaded into a vesicle and the vesicle travels to its destination where it will
then fuse with the acceptor membrane and deliver its cargo. Since there are many
membrane-bound compartments within a cell, consequently there are many potential
places for a vesicle to incorrectly deliver its cargo. In order to avoid this, vesicular
transport is a highly regulated process and consists of many factors that each contribute to
ensure that each vesicle reaches the correct destination. These factors include Rabs,
guanine nucleotide exchange factor (GEFs), tethers, and soluble N-ethylmaleimide-
sensitive factor attachment protein receptors (SNAREs) whose identities vary depending
on the trafficking pathway (Pfeffer, 1999). In the pathway between the endoplasmic
reticulum (ER) and the Golgi, the formation of the vesicle begins with the recruitment of
the COP II coat components onto the ER membrane; the transmembrane-anchored and
ER-resident protein, Secl2 recruits the GTPase, Sari onto the ER membrane. Binding of
Sari to the ER then allows the GTPase activating protein (GAP), Sec23 and the cargo
recruiter, Sec24 to form a complex with Sari. Finally, deformation of the membrane and
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stabilization of the polymerizing coat occurs after binding of the Sec 13/31 complex to the
Sec23/24 complex (Matsuoka et al, 1998; Bielli et al., 2005). Once formed, the vesicle
then travels to the Golgi where extended coiled-coil proteins such as pi 15,
GM130/golgin-95 in mammalian cells and Uso Ip in yeast interact with the coat proteins
and tether the vesicle to the target membrane. Further specificity is established by a
second tethering action carried out by the multi-subunit tethering complex called
Transport Protein Particle (TRAPP) (Kim et al., 2006). Fusion of the vesicle and target
membrane then occurs subsequent to SNARE interactions that form a highly stable
SNAREpin complex, composed of one SNARE from the vesicle and three SNAREs from
the target membrane. The SNAREs found on the vesicle and the target membrane are
called v- and t-SNAREs respectively (vesicle- and target SNAREs) or they may also be
referred to as R- and Q-SNAREs respectively, where the latter terminology refers to a
conserved residue essential to the formation of a stable SNAREpin complex (Fasshauer et
al., 1998). At this point, vesicular trafficking is complete since the vesicle has
successfully reached its target membrane and fused at the appropriate destination.
1 .2 Membrane Trafficking and Diseases
The eukaryotic cell contains several membrane-bound compartments that each
perform a unique function essential to the cell. To maintain the identity of each
membrane-bound compartment, it is crucial that the trafficking of all cellular components
be tightly regulated since a single mistake may lead to severe and undesirable outcomes
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including cell death (Aridor and Hannan, 2000; Aridor and Hannan, 2002). Fortunately,
the cell has several mechanisms to deal with various errors and thus allow cell activity to
proceed as normal. One example is when newly synthesized proteins are packaged from
the ER and taken to the Golgi for further post-translational modifications and/or sorting.
Normally only the proteins destined for the secretory pathway are packaged into vesicles
for transport, however, sometimes an ER-resident protein is accidentally loaded into the
vesicle as well. To rectify this situation ER-resident proteins possess a sequence such as
KDEL or KKXX at the C-terminus that mediates their return to the ER (Munro and
Pelham, 1987; Nilsson et al., 1989). Through the use of signal-peptide sequences that
mediate the localization of specific proteins to specific compartments, the cell is able to
ensure the continued fidelity of intracellular trafficking.
However, sometimes defects go uncorrected by the cell. In the latter case the
outcome varies depending on the type of error that occurred. When mutations are present
in the coding sequence of a protein, sometimes the mutation may lead to the improper
folding of the protein or may impair the function of the protein. In either case, the protein
is unable to successfully perform its duty and the result is usually disease. In humans,
there are many examples of mutations and/or loss of components of vesicular transport
that are known to lead to disease. One example is Huntington's disease (HD), where HD
is characterized by psychiatric problems, depression and hyperkinetic involuntary
movements (Harper, 1996). This disease is caused by a mutation in the gene, ITl 5 which
encodes a protein product called, huntingtin (Macdonald et al., 1993). The mutation
affects gene transcription, protein-protein interactions, intracellular transport,
neurotransmitter synthesis, release and neurotransmitter receptors. In HD patients a loss
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of SNAP-25 (soluble iV-ethylmaleimide-sensitive factor attachment protein receptor
(SNARE) protein) and rabphillin 3a was reported (Smith et al., 2007), where the former
is a Q-SNARE involved in fusion events at the plasma membrane (PM) and the latter is
involved in vesicle docking and recycling, and where both proteins are crucial for
neurotransmitter release. It is thought that a deficient pre-synaptic transmitter release due
to loss of SNAP-25 and rabphillin 3a may explain some of thè symptoms of HD. Another
example is arthrogryposis-renal dysfunction-cholestasis (ARC) syndrome that is caused
by a mutation in the VPS33B gene which subsequently leads to dysregulation of vesicle
fusion (Gissen et al., 2004). These examples are only two of the many diseases that have
been linked to defects in intracellular transport. Nonetheless, the message is clear that
proper intracellular trafficking is crucial in maintaining optimal cellular conditions.
1 .3 Tethers in Membrane Trafficking
There are many trafficking pathways within a eukaryotic cell (Whyte and Munro,
2002). Therefore, due to the abundance of trafficking pathways it is not impossible to
imagine that each pathway contains its own set of players that impart the specificity of
vesicle targeting and fusion to the acceptor membrane. As mentioned above, one of the
first factors that determines the specificity of vesicle targeting are the tethers. In the
eukaryotic cell, the tethers may be grouped into two different classes: long coiled-coil
proteins and multi-subunit complexes.
To date, long coiled-coil proteins are known to be involved in Golgi and in
endosomal fusion (Nielsen et al., 2000), however none have been associated with other
transport steps. And because of their length which spans up to several times the diameter
of a vesicle, it has been proposed that this class of tethers may be one of the first
components to confer specificity to the targeting process by being anchored at one end to
the acceptor membrane and using its other end to search the surrounding area for
incoming vesicles (Lowe, 2000; Pfeffer, 1996; Waters and Hughson, 2000; Whyte and
Munro, 2002). However, as of yet, there has been no direct evidence supporting this
hypothesis. Some coiled-coil proteins are Uso Ip in yeast which is required for the
tethering of ER-derived vesicles to acceptor membranes (Barlowe, 1997), pi 15 which is
the mammalian homologue of Uso Ip and tethers COP I vesicles to the Golgi (Sonnichsen
et al., 1998) and EEAl which is required for the tethering of vesicles to the endosóme
(Dumas et al., 2001).
The second class of tethers consists of eight multi-subunit complexes that can be
further divided into two distinct groups: three quatrefoil tethering complexes that are
related to each other through a shared domain at the N-terminus (Whyte and Munro,
2002), and five non-quatrefoil tethering complexes that do not share any common
domain. The three quatrefoil tethering complexes are the exocyst, conserved oligomeric
Golgi (COG) and Golgi-associated retrograde protein (GARP), while the five non-
quatrefoil tethering complexes are TRAPP I, TRAPP II, /zomotypic fusion and vacuole
protein sorting (HOPS), class C core vacuole/endosome tethering (CORVET) and DsI Ip
(Whyte and Munro, 2002; Markgraf et al., 2007). In addition to sharing a common
domain the former group also shares another similarity; each of the quatrefoil complexes
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contains a multiple of four subunits which may reflect the ability to interact with a
SNAREpin as tentatively proposed by Whyte and Munro (2002). And with regards to the
entire class of multi-subunit complexes, structural similarity between subunits within a
complex appears to be an emerging theme. In the exocyst, structural similarity between
long a-helical rod structures of Exo70p and the C-terminal domains of Sec6p, Exo84p
and Seel 5 have been observed (Dong et al., 2005; Sivaram et al., 2006), and structural
similarity between subunits has been speculated for the COG complex (Dong et al., 2005;
Cavanaugh et al., 2007; Whyte and Munro, 2002). In the vertebrate TRAPP complex, the
subunits can be grouped into two families: the bet3 family consisting of TRAPPC3,
TRAPPC5 and TRAPPC6 and the sedlin family consisting of TRAPPCl, TRAPPC2 and
TRAPPC4 (Sacher et al., 2008). At the structural level, along with the exocyst, TRAPP is
one of the best studied multi-subunit tethering complexes to date and consequently is
quickly becoming one of the complexes whose characterization is progressing steadily
with time. It is now known that mutations in certain subunits of TRAPP lead to various
trafficking disorders and sometimes disease (Chiari et al., 1999; Gedeon et al., 1999),




Just over a decade ago, TRAPP (Transport Protein Particle) was discovered as a
novel and highly conserved tethering complex reported to participate in protein secretion
(Sacher et al., 1998). Initial studies on TRAPP revealed the complex to be approximately
800 kDa in size and through fluorescence localization and subcellular fractionation
studies, TRAPP was found to localize to the c/s-Golgi. Subsequent work showed that the
800 kDa complex was one member of a pair of large complexes and was therefore called
TRAPP II. A smaller and highly-related complex was found and called TRAPP I. While
TRAPP II participates in membrane trafficking at a late Golgi compartment (Sacher et
al., 2001; Cai et al., 2005), TRAPP I was found to mediate ER-to-Golgi transport (Sacher
et al., 1998; Sacher et al., 2001).
The discovery of the TRAPP complexes came about through an
immunoprecipitation study that was performed in order to gain insight into the function
of the protein product of the BET3 gene. A mutant in the BET3 allele was identified in a
yeast genetic screen as synthetically lethal with a betl mutation, the latter being a gene
whose protein product acts in ER-to-Golgi transport (Rossi et al., 1995). Using a
radiolabelled yeast cell lysate containing c-/rayc-tagged Bet3p, Bet3p and its interacting
partners were pulled down using an antibody directed against the c-myc tag. The
corresponding sodium dodecyl sulphate - Polyacrylamide gel electrophoresis (SDS-
PAGE) revealed that nine other protein products precipitated with c-myc-Bet3p, and
through the use of mass spectrometry the protein products were identified. The proteins
are referred to as Trs20p, Trs23p, Trs33p, Bet5p, Trs31p, Trs85p, Trs65p, Trsl20p and
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TrsBOp (Sacher et al., 1998; Sacher et al., 2000). While the first seven subunits are
found in both TRAPP complexes, the latter three are unique to the TRAPP II complex
(Sacher et al., 2001).











YML077W Bet5p(18) TRAPPCl (17) MUM-2
YBR254C Trs20p (20) TRAPPC2 (16) Sedlin
YKR068C Bet3p (22) TRAPPC3 (20)
YDR246W Trs23p (23) TRAPPC4 (24) Synbindin
YDR472W Trs31p(31) TRAPPC5 (21)
YORl 15C Trs33p (33) TRAPPC6a,b(18)
YGR166W Trs65p (65) None
YDR108W Trs85p (85) None
YDR407C Trsl20p(120) TRAPPC9 (140) NIBP
YMR218C TrsBOp (130) TRAPPClO (142) TMEM-I
Note: The above table is adapted from Sacher et al., 2008.
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1.3.1.1 Assembly and Structure of TRAPP I
Since the discovery of TRAPP much research and insight has been gained
concerning the structure and function of TRAPP and TRAPP subunits. Recently, the
structure of the yeast S. cerevisiae and mammalian TRAPP I was solved. In both cases
TRAPP I has an elongated, flat architecture with dimensions of -180 Â ? 65 Â ? 50 Â
(length ? width ? height) (Kim et al., 2006; Cai et al., 2008). Recombinant yeast and
mammalian TRAPP I subcomplexes have been produced in Escherichia coli (E. coli). In
yeast, recombinantly-expressed subunits of TRAPP I spontaneously form one stable
complex where the tetrameric subcomplex: Bet3p-Trs33p-Bet5p-Trs23p is linked to the
trimeric subcomplex: Bet3p-Trs31p-Trs20p. The two subcomplexes are linked through an
interaction between Trs23p and Bet3p-Trs31p. An analogous recombinant mammalian
TRAPP I complex did not assemble into one stable complex, rather the two stable
subcomplexes mentioned above remain separate. Currently it is not known why the
mammalian subcomplexes do not assemble into one complex as observed for the yeast
proteins. However, it has been suggested that perhaps mammalian TRAPP I requires an
as yet unidentified subunit to join the two subcomplexes together, or that a
posttranslational modification is required for assembly (Kim et al., 2006; Sacher et al.,
2008).
Nevertheless, despite the inability of the recombinant mammalian proteins to
form one stable complex, the architecture of mammalian TRAPP I was elucidated by
docking the crystal structures of the two mammalian subcomplexes into the electron
microscopic (EM) density map of the yeast complex (Kim et al., 2006). Because the
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crystal structure of the mammalian subcomplexes fit nicely into the density map of the
yeast complex, the observed elongated flat structure of the TRAPP I complex is thought
to be a conserved feature.
1.3.1.2 First Model of TRAPP I as a Tether
Early studies on the TRAPP I complex lead to the hypothesis that TRAPP I
functions in the trafficking between the ER and the Golgi (Sacher et al., 1998). Today
this hypothesis has been further characterized and supported by several groups (Sacher et
al., 1998; Sacher et al., 2001; Jiang et al., 1998; Rossi et al., 1995), and it has been found
that TRAPP I functions as a tethering factor for vesicles travelling from the ER to the
Golgi.
Recently, two models have been proposed for TRAPP I mediated-vesicle
tethering. In the first model (Kim et al., 2006) one of the first tethering interactions
occurs by long, extended coiled-coil proteins such as pi 15 and/or GM130/golgin-95 in
mammalian cells and by Uso Ip in yeast. Once the vesicle is tethered, the coiled-coil
proteins undergo a bending motion which brings the ER-derived vesicle closer to the
Golgi where the vesicle can interact with another tethering factor, TRAPP I. In this model
TRAPP I lies flat on the Golgi and lengthwise which means that 180 Â ? 65 Â of TRAPP
I is exposed for interaction with the incoming vesicle. This would also mean that the
vesicle is now approximately 50 Â away from the Golgi and is thus within range for
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SNAREpin formation. Fusion is then driven by the formation of a stable SNAREpin
structure allowing for the release of the vesicle contents.
1.3.1.3 Second Model of TRAPP as a Tether
The second model is similar to the first, differing only in the way that TRAPP I is
proposed to be oriented on the Golgi and/or acceptor membrane (Cai et al., 2008). In the
second model TRAPP I is proposed to project lengthwise from the acceptor membrane.
In this position it would interact with both the donor and acceptor membrane via
conserved residues in the Bet3 subunit. Like the first model, this model is also plausible
because it has been shown that TRAPP I mediates homotypic tethering between two COP
II coated vesicles (Yu et al., 2006), and because Bet3p interacts with the Sec23p subunit
of the COP II vesicle coat (Cai et al., 2007).
In both models, the common theme is that several factors are required in the
docking of a vesicle to the acceptor membrane. The presence of several factors is
necessary to ensure specificity because some factors such as GM130/golgin-95 are
involved in processes elsewhere in the cell (Moyer et al., 2001). However, the main
difference between the two models is that the first attempts to explain heterotypic fusion
while the second attempts to explain both hetero- and homotypic fusion. In mammalian
cells, both models are equally possible since both types of fusion events have been
observed. However, in yeast cells homotypic fusion has not been reported. It has been
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suggested that both models are not mutually exclusive but instead reflect the need of the
complex to mediate two different types of fusion events (Sacher et al., 2008).
1 .4 TRAPP as a Guanine Nucleotide Exchange Factor (GEF)
Another interesting feature of TRAPP - and perhaps connected to the tethering
ability of the complexes - is the fact that both TRAPP complexes have GEF activity.
GEFs are important because they stimulate the activation of specific Rabs by promoting
the exchange of guanosine diphosphate (GDP) for guanosine triphosphate (GTP), which
subsequently allows the activated Rab to regulate specific pathways within the cell. In the
vesicular pathway between the ER and the Golgi, and after the tethering of the vesicle to
the acceptor membrane, the activated form of the Rab, Yptlp is believed to recruit
downstream effector molecules which then promote the fusion of donor and acceptor
membranes (Kim et al., 2006). Previous work has shown that TRAPP I is a GEF for
Yptlp while TRAPP II is a GEF for Ypt31/32p (Wang et al., 2000; Jones et al., 2000).
1.4.1 TRAPP I: GEF for Yptlp
The TRAPP I core subunits required for GEF activity were elucidated to be two
copies of Bet3p (Bet3-A and Bet3-B), Bet5p, Trs23p and Trs31p (Kim et al, 2006).
More recently, the structure of the core subunits in complex with Yptlp was solved (Cai
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et al., 2008) which provided insight into the GEF activity of TRAPP I. It was observed
that of the five core subunits only four subunits directly interacted with Yptlp: Trs23p,
Bet5p and the two copies of Bet3p. However, although Trs31p does not directly interact
with the surface of Yptlp, it is thought to be important in the formation and maintenance
of the Yptlp-TRAPP I interface (Cai et al., 2008). Furthermore, the crystal structure
revealed that the C-terminus of the Bet3p-A protein occupies a similar position as the
guanine nucleotide. This latter observation was noted by Cai et al. (2008) and suggests
that the C-terminus of the Bet3p-A is responsible for initiating the exchange of GDP for
GTP by inserting into the GTP-binding pocket of Yptlp and acting as a wedge to initiate
the conformational change required for GDP release. Although the latter model is
certainly attractive, the fact that deletion of the C-terminus of Bet3p does not lead to a
growth defect in yeast suggests refinement of this model is necessary. Therefore, further
work remains to clarify whether the C-terminus of the Bet3p-A subunit is responsible for
activating Yptlp, and whether TRAPP I activates Yptlp through an alternate method.
1 .4.2 TRAPP II: GEF for Ypt3 l/32p
Compared to TRAPP I less is known about the GEF activity of TRAPP II at the
structural level. Furthermore, it remains a controversial subject because various groups
have shown results that appear to contradict each other. One piece of evidence that
supports TRAPP II as a GEF for Ypt31/32p is that when Trsl20p and/or Trsl30p (both
TRAPP II specific subunits) is mutated, Ypt31/32p GEF activity is abolished while
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Yptlp GEF activity is increased (Morozova et al., 2006). Conversely, another group has
shown that TRAPP II is not a GEF for Ypt32p, but rather is a GEF for Yptlp (Wang et
al., 2000; Wang and Ferro-Novick, 2002). It has been suggested that these contradictory
results may be a reflection of the different preparation methods used by each group
(Sacher et al., 2008). However, what the surrounding controversy does make clear is that
further work is required to resolve the current dispute surrounding the GEF activity of
TRAPP II.
1.5Sedlin
The TRAPP complexes have seven subunits in common, one of which is a protein
called sedlin. In mammalian cells sedlin is also known as TRAPPC2, while in yeast cells
sedlin's orthogue is called Trs20p. Sedlin is a small protein of 140 amino acids (aa) and
sits at the extremity of the TRAPP complex where it is thought to participate in multiple
protein-protein interactions. A connection between membrane traffic and skeletal
development was revealed when it was found that patients with the disorder
»Spondyloepiphyseal dysplasia iarda (SEDT) all had mutations in the gene encoding for
sedlin (Gedeon et al., 1999). Currently, very little is known about the role(s) and
function(s) of sedlin, however, several functions have been suggested in light of its
presence in the TRAPP complex and its involvement in SEDT (Jang et al., 2002b; Kim et
al., 2006). Additionally, sedlin has also been implicated in gene regulation after it was
identified to be an interacting partner of c-myc promoter-binding protein 1 (MBP-I),
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where MBP-I is a protein that binds to the c-myc promoter and represses promoter
activity (Ghosh et al., 2001).
1.5.1 Role of Sedlin in ER-to-Golgi Trafficking
As previously mentioned, sedlin is part of a large multi-subunit tethering complex
called TRAPP. Within this complex, sedlin sits at one end where it may participate in
multiple protein-protein interactions. Currently, the function(s) of sedlin is not known,
however, sedlin is not required for the GEF activity of TRAPP (Kim et al., 2006).
Therefore, what could be the function of sedlin in the TRAPP complex? It was suggested
that sedlin may possess a regulatory and/or an adaptor role in trafficking between the ER
and the Golgi by interacting with neighbouring SNAREs, since the crystal structure
revealed that despite a lack of sequence similarity, sedlin is structurally similar to the N-
terminal domain of two SNARE proteins, Ykt6p and Sec22p (Jang et al., 2002b).
Furthermore, it was noted that the three proteins possess a common hydrophobic surface
between a? and ß3. In Yktóp this surface participates in the formation of the closed
conformation, where the latter conformation prevents the association of R- and Q-
SNAREs from forming the core complex which occurs prior to membrane fusion (Tochio
et al., 2001), while in Sec22p the hydrophobic surface is involved in crystal -packing
interactions (Gonzalez, Jr. et al., 2001). Additionally, sedlin was also found to possess
many solvent-exposed apolar residues which is an unusual property for a protein.
However, this unusual property suggests the fact that sedlin may participate in multiple
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protein-protein interactions (Jang et al., 2002b), and some of these residues were indeed
subsequently found to participate in interactions with other known TRAPP subunits (Kim
et al., 2006).
1 .5.2 Mutations in sedlin lead to Spondyloepiphyseal dysplasia iarda (SEDT)
To date, greater than 30 different mutations in sedlin have been documented that
cause SEDT (Savarirayan et al., 2003; Gecz et al., 2003), where SEDT is an X-linked
recessive disorder whose onset occurs around the ages of ~10 - 15 years. SEDT affects
the spinal vertebral bodies and epiphyses during skeletal growth and as a result affected
individuals possess a short trunk and are of short stature (MacKenzie et al., 1996).
Although this disorder is not life-threatening it is nonetheless debilitating since affected
individuals develop premature arthritis predominantly in the spine and hip joints, and in
the third decade of life usually require surgery to reduce joint pain (Taybi and Lachman,
1996). Currently, there is no specific treatment for SEDT, however healthy eating,
maintaining a healthy weight-for-height, and regular low-impact exercise such as
swimming or cycling is advised (Savarirayan et al., 2003).
Although there have been a variety of documented mutations in the gene encoding
for sedlin that lead to SEDT no correlation has yet been found between the location of the
mutation and the observed effect on the phenotype as all mutations lead to the appearance
of SEDT with no varying degree in the severity of the symptoms (Gedeon et al., 2001).
However, in yeast, various mutations in the sedlin gene exhibit subtle differences. Some
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mutations known to cause SEDT in humans were able to complement a TRS20 disruption
while others could not (Gedeon et al., 2001). The latter observation was explained in two
ways. Either in humans the clinical differences between each individual are so subtle that
they escape detection, or the functions of sedlin and Trs20p are different in metazoan and
non-metazoan eukaryotes. The fact that human sedlin can compensate for Trs20p (Gecz
et al., 2003) suggests that perhaps sedlin and Trs20p share some overlapping and/or
similar function(s).
Thus far it is clear that mutations in the sedlin gene cause SEDT, however the
molecular mechanism of how SEDT develops remains to be elucidated. Currently several
scenarios have been suggested. One possibility is that sedlin mutations impede proper
collagen secretion and thus normal bone growth is affected. Another possibility is that
sedlin has a function independent of the trafficking pathway and disruptions in this
independent function lead to SEDT (Sacher, 2003). Therefore by studying sedlin/Trs20p
and sedlin-related proteins insight into the function and role of sedlin may be gained.
1.5.3 Sedlin pseudogenes and sedlin-related proteins
The fact that SEDT is an X-linked recessive disorder not only indicates the
genetic nature of the disorder but it also reveals the fact that only one functional copy of
sedlin is sufficient to suppress the SEDT phenotype. This fact is supported through the
observation that female carriers do not display the SEDT phenotype. The latter
observation brings up an interesting issue because if one copy of sedlin is sufficient to
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carry out the function(s) of sedlin, then what happens when the protein product of an
open reading frame (ORF) identical to the sedlin gene and sedlin-related genes comes
into the picture? More precisely the question is, can the latter protein products contribute
and/or fulfill the role(s) and function(s) of sedlin? Since sedlin has one retropseudogene
and one sedlin-related protein, by answering the latter question insight may be gained
concerning the function(s) and role(s) of sedlin.
In the human genome there are a total of seven pseudogenes. However, out of the
seven, one is a retropseudogene: C2.19 (also known as SEDLPl) located on chromosome
19 (Gecz et al., 2000). The retropseudogene C2.19 is interesting because it contains an
ORF identical to the sedlin ORF. Moreover, it is intriguing that C2.19 has been shown to
be transcribed and potentially translated (Ghosh et al., 2001; Scrivens et al., 2009), which
could potentially allow the protein product of C2.19 to compensate for a lack of sedlin in
the cell. As well, tissue-specific expression of C2.19 may also explain why SEDT is
tissue specific and why there is a lack of severe growth defects in SEDT patients.
Most recently a sedlin-related protein was identified and is called, TRAPPC2L
(TRAPPC2-like and will be herein referred to as C2L) (Scrivens et al., 2009). This
protein was found through a Basic Local Alignment Search Tool (BLAST) using the
yeast Trs20p as the query and is 27% identical to Trs20p and 28% identical to sedlin.
Interestingly, like sedlin, C2L interacts with the TRAPP complex as shown by size
exclusion chromatography using mammalian cell lysates (Scrivens et al., 2009). C2L
does not appear to replace sedlin in the complex, rather it has been proposed that C2L sits
at the opposite extremity of the complex compared to sedlin (Figure 1.1). Whether C2L
may compensate for a lack of sedlin in the cell has yet to be shown, however the fact that
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the D47 residue (known to cause SEDT when changed to tyrosine) is conserved from
sedlin to C2L may suggest a conserved function. On the other hand, phylogenetic
analysis revealed that sedlin and C2L occur in pairs across species which suggests a
conserved functional divergence. Further supporting a functional divergence, it has been
shown that C2L is unable to compensate for a loss of Trs20p in yeast (Scrivens et al.,
2009). Nonetheless, C2L may compensate for a lack of sedlin since G2L is a sedlin-
related gene exhibiting 28% identity to sedlin. Further work remains to be done to shed













Note: The above image is adapted from (Sacher et al., 2008).
Figure 1.1: Mammalian TRAPP. TRAPP consists of seven subunits as seen above.
Within the complex sedlin sits at one extremity while the novel TRAPP interactor, C2L,
is believed to sit at the opposite extremity. Note that C2L is not shown above.
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1 .5.4 Sedlin and Other Possible Functions
In addition to a role in membrane trafficking and a role in SEDT, sedlin has been
suggested to have a role in gene regulation. As mentioned above, sedlin was found to
interact with a protein called MBP-I that binds to the c-myc promoter and represses
promoter activity which in turn leads to apoptosis (Ghosh et al., 2001). The binding of
sedlin to MBP-I was found to relieve the repression caused by MBP-I and thus decrease
apoptosis. In a follow-up study (Ghosh et al., 2003) it was found that expression of sedlin
was able to repress luteinizing hormone ß (LHß) promoter activity, where regulated LHß
expression is crucial for reproduction (Tremblay and Drouin, 1999). In the latter study,
the regulation of the LHß gene was studied because sedlin was found to be expressed
predominantly in systems related to reproduction such as testis and pituitary, and other
tissues such as the right cerebellum and adrenal glands (Ghosh et al., 2003). Another
study revealed sedlin was found to interact with chloride intracellular channel (CLICl
and CLIC2) proteins (Fan et al., 2003). The latter proteins are thought to be involved in
homeostasis of membrane potential, maintenance of intracellular pH and control of cell
volume. Currently, the significance of the latter interaction is unknown however the
apparent interaction between the respective proteins suggests sedlin may aid in one or
more of the aforementioned functions of the CLIC proteins, or may recognize the CLIC
proteins as cargo on a vesicle.
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1.6 Project: A yeast two-hybrid screen identifies a novel interactor of the TRAPP
subunit sedlin
As seen above, currently the function of sedlin is unknown. Nevertheless, sedlin
has been implicated in trafficking between the ER and the Golgi due to its presence in the
TRAPP complex and is implicated in the skeletal disorder, SEDT. In addition, sedlin may
have a role in gene regulation as well as an as-yet undefined function within the cell. In
this project I use a yeast two-hybrid screen (Y2H) to identify interacting partners of
sedlin in order to further characterize and gain a deeper insight into its function.
1 .6.1 Yeast two-hybrid (Y2H)
Developed in 1989 (Fields and Song, 1989), the Y2H screen remains one of the
leading molecular tools to study protein-protein interactions in native intracellular
conditions. This screen is not oniy inexpensive, but can also be carried out in almost any
laboratory with results seen within a matter of days. In addition, compared to other
methods used to study protein-protein interactions such as crosslinking and co-
immunoprecipitation, the Y2H screen allows one to detect transient interactions that may
not be normally detected in the former approaches. This innovative technology employs
the GAL4 transcriptional activator and takes advantage of the fact that GAL4 can be
physically separated into two domains whose function can be re-established once the two
domains are brought into proximity. In the classic Y2H screen two fusion proteins are
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required: a protein of interest fused to the DNA binding domain (BD) of GAL4 (also
referred to as the bait protein) and the library protein(s) fused to the activation domain
(AD) (also referred to as the prey protein). Interaction between the bait and prey protein
brings the BD and AD of GAL4 close enough together to allow transcription of the
downstream reporter genes that subsequently allows growth on selective media.
However, although the classic Y2H screen is an attractive method to study a
protein there are also some limitations. One limitation is that although this screen occurs
within yeast cells and thus occurs under native cellular conditions, the bait and prey
protein must both be able to translocate to the nucleus in order to allow transcription of
the reporter gene. Therefore, interactions between the bait protein and membrane-bound,
integral membrane and/or proteins localized to subcellular compartments cannot be
detected and would generate what is called a false negative. Further, the bait and prey
protein should not be able to autoactivate the reporter gene which would lead to the
appearance of false-positives. False positives are one of the biggest drawbacks of the
Y2H screen because the appearance of false positives may occur for multiple reasons,
such as the one just mentioned or non-specific interactions. However, these limitations
can be overcome. If the bait or prey protein autoactivates the reporter gene(s) then by
using increasing concentrations of 3-amino-l,2,4-triazole (3AT) the expression of the
HIS3 gene product (which is one of the reporter genes in the Y2H screen) is inhibited
accordingly. To distinguish false positives from the real interactors, the identified
interaction should be verified through other methods such as pull-down assays and
coimmunoprecipitations. Finally, in order to overcome the generation of false negatives
other Y2H systems have been developed: the SOS- and the RAS recruitment systems
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(SRS and RRS) (Hubsman et al., 2001) which detects interactions with membrane-bound
proteins and the Split-ubiquitin system (Stagljar et al., 1998) which detects interactions
occurring between cytosolic proteins and membrane proteins.
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2. Materials and Methods
2.1 Plasmid constructs, Oligonucleotides and Strains
For the Y2H screen, the bait construct (pGBKT7-sedlin) was made by amplifying
mouse sedlin using the oligonucleotides sedlinFEcoRI and sedlinREcoRI (Table 2.1)
followed by ligation into the bait vector, pGBKT7 (Clontech). Standard amplification
mixture contained Ix polymerase buffer, 200 µ? dNTP, -30 ng template DNA, 500 nM
forward oligonucleotide, 500 nM reverse oligonucleotide, 1 .25 U of polymerase. The
correct orientation was selected for following a digest with Mscl where the expected
fragment sizes were 4786, 2895 and 49 base pairs (bp) for the correct orientation and
4786, 2539 and 405 bp for the incorrect orientation. SPATA4 constructs were prepared
by amplifying the ORF from mouse testis cDNA, which was a kind gift from Dr. James
Scrivens from Concordia University, using the oligonucleotides SPATA4-F-HindIII,
mSPATA4-R-BamHI, SPATA4-F-BamHI and mSPATA4-R-XhoI (Table 2.1). The
amplified product of the two former and the two latter oligos respectively was ligated into
pFLAGCMV6a (Sigma) and pMALc2X (New England Biolabs) respectively. To
generate the pGBKT7-sedlin (APA) construct the QuikChange® protocol (Stratagene)
was followed and oligonucleotides C2APAUP and C2APADN were used to
introduce the APA mutation into the template, pGBKT7-sedlin. All other
oligonucleotides, strains and plasmid constructs used in this study can be found in Tables
2.1, 2.2 and 2.3 respectively. All bacterial strains were grown at 37°C for 16 hours, while
25
all yeast strains were grown at 300C for 48 hours unless otherwise indicated. All liquid






































































































































































































































































































































































































































































































































































































































































































































































































































































































2.2 Tissue Culture and preparation of cell lysates
Human embryonic kidney 293T (HEK 293T) cells were grown in Dulbecco's
modified Eagle Medium (DMEM) supplemented with 10% fetal bovine serum (FBS,
Wisent) and 1% penicillin/streptomycin (P/S).Cells were kept in a humidified 5% CO2
chamber at 37°C. Transfections were carried out in either 10 (for coimmunoprecipitation)
or 15 (for gel filtration) cm dishes with 10 or 20 µg of DNA, respectively, using the
calcium phosphate method as described below (Section 2.2.1). Cells were harvested 48
hours post-transfection by scraping with 500 or 1 ,000 µ? coimmunoprecipitation (CoIP)
lysis buffer (1% Triton X-IOO, 1 mM EDTA, 50 mM Tris pH 7.5, 150 mM NaCl) with 1
mM sodium orthovanadate and protease inhibitor (Roche) for 10 or 15 cm dishes,
respectively. For gel filtration, cells were collected as above using gel filtration lysis
buffer (150 mM NaCl, 50 mM Tris pH 7.2, 0.5 mM EDTA, 1 mM DTT, 1% Triton ?-
? 00) with protease inhibitor (Roche). For western analysis 30 µg of lysate was used.
2.2.1 Calcium phosphate transfection
Cells were plated at -50% confluence and grown in supplemented DMEM as
indicated above (section 2.2). The following day, cells were transfected with 1 ml of
transfection mixture (Ix Hepes buffered saline (HBS; 25 mM HEPES, 0.75 mM
Na2HPO4, 5 mM KCl, 140 mM NaCl, 6 mM dextrose), 10-20 µg DNA and 84 mM
calcium chloride). The medium was replaced with fresh medium 24 hours post-
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transfection. Cells were harvested 48 hours post-transfection as indicated above (section
2.2).
2.4 Yeast two-hybrid screen (Y2H)
2.4.1 Mating the bait with the prey strain
The Y2H screen was performed as described in the Matchmaker™
Pretransformed Libraries User Manual. Briefly, a 50 ml culture of the bait strain (AH 109
containing pGBKT7-sedlin) was grown to an OD6oo of 0.8-0.9 in -Trp medium and then
centrifuged at 1,000 g for 5 minutes and resuspended in 5 ml of -Trp medium. Then, 1
ml of the prey strain (Pretransformed Normalized Matchmaker™ Human Universal
cDNA Library in Y 187 (Clontech)) was added and the total volume of the culture was
brought to 50 ml using 2x YPDA (0.1% yeast extract, 0.2% peptone, 0.2% dextrose,
0.3% L-adenine hemisulphate). The cells were mated for 24-28 at 300C hours with
shaking at 50 rpm. Cells were subsequently plated on quadruple drop out (QDO; 0.67%
yeast nitrogen base, 2% dextrose, 0.08% -Trp/-Leu/-His/-Ade dropout mix) solid medium
containing X-a-Gal and left at 3O0C for 3-8 days.
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2.4.2 Analysis and Verification of putative positive clones
2.4.2.1 Retesting phenotypes
To ensure that each positive clone contained only one prey plasmid, positive
clones were streaked on double drop out (DDO) (0.67% yeast nitrogen base, 2%
dextrose, 0.08% -TrpALeu dropout mix) solid medium containing X-a-Gal. One clone
from the latter plate was then picked and streaked onto triple drop out (TDO) (0.67%
yeast nitrogen base, 2% dextrose, 0.08% -Trp/-Leu/-His dropout mix) solid medium
containing X-a-Gal to verify that the phenotype was maintained. If a clone contained
more than one prey plasmid then a mixture of blue and white colonies would result after
streaking.
2.4.2.2 Colony polymerase chain reaction (PCR)
Positive clones were picked and inserts in pGADT7 were amplified via
polymerase chain reaction (PCR) using oligonucleotides pGAD-F-ID and pGAD-R-ID.
The conditions for PCR consisted of: 1 cycle of 940C for 3 minutes, followed by 30
cycles of 94 seconds for 30 seconds, 68 0C for 3 minutes, 72 0C for 7 minutes, ending
with an elongation step of 72 0C for 7 minutes. The identity of the amplified products was
determined by DNA sequencing.
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2.4.2.3 Rescuing plasmici DNA from yeast and bacterial transformations
Plasmids were rescued from yeast cells as described in the adapted protocol by
Michael Jones based on the QIAprep® Spin Miniprep Kit protocol (Michael Jones,
Chugai Institute for Molecular Medicine, Ibaraki, Japan). The adapted version employed
acid washed glass beads (Sigma) to mechanically lyse the yeast cells after resuspension
in resuspension buffer (Fermentas). Purification of the plasmid proceeded as per the
manufacturer's instructions. Following the rescue of the plasmid from the yeast cells, the
plasmid was transformed into electrocompetent DH5a bacterial cells to amplify the
plasmid. Transformations were done using 0.5-2 µ? of DNA in 40 µ? of electrocompetent
cells. Cells were briefly shocked in a sterile 2mm electroporation cuvette and grown in 1
ml of SOC (2% tryptone, 0.5% yeast extract, 10 mM NaCl, 2.5 mM KCl, 10 mM MgCl2,
10 mM MgSO4, 20 mM Glucose) at 37°C for 1 hour, followed by plating on solid luria-
Bertani medium (LB) (0.5% yeast extract, 1% tryptone, 1% NaCl) containing the
appropriate antibiotic.
2.4.2.4 High efficiency yeast transformations
High efficiency yeast transformations were done as described by Gietz and
Woods (2002). Briefly, 50 ml cultures were grown to an OD600 of 2.0 and made
competent after washing with sterile water and resuspension in an appropriate volume of
transformation master mix (33.3% polyethylene glycol 3500, 100 mM lithium acetate,
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1 .4 µ^µ? boiled single-stranded-carrier DNA). Cells were then incubated in a 42°C water
bath for 40 minutes. Prior to plating, cells were pelleted by centriftigation at 13,200 rpm
for 30 seconds in a table top microcentrifuge and pellets resuspended in either 0.5 or 1 ml
of sterile water. Cells were plated on the appropriate selective solid medium and
incubated at 300C for 2-4 days.
2.5 Coimmunoprecipitation using HEK 293T cell lysates
HEK 293T cells were co-transfected as above (section 2.2.1) with pRK5MYC-
sedlin and pFLAGCMV6a-SPATA4 constructs and the appropriate controls. CoIP
samples contained 1 mg of lysate (prepared as in section 2.2) made up to a total volume
of 1 ml with Ix phosphate buffered saline (PBS; 8% NaCl, 0.2% KCl, 1.44% Na2HPO4,
0.24%o KH2PO4). Immunoprecipitation was done with 2 µg of rabbit anti-myc
IgG(Abcam) on ice, at 40C for 16 hours, followed by incubation with 10 µ? of Protein A-
agarose (Bioshop), on a nutator at 4°C for 2 hours. Samples were then washed 3x with 1
ml Ix PBS with spinning in a refrigerated microcentrifuge for 30 seconds at 5,000 rpm.
Finally, 25 µ? of Ix sample buffer (SB) (62.5 mM Tris-HCl pH 6.8, 2% SDS, 7.5%
Glycerol, 0.005% Bromophenol Blue, 2.5% ß-mercaptoethanol (Bioshop)) was added to
samples, heated at 950C for 2 minutes and either stored at -2O0C or loaded on a SDS-
PAGE gel for Western analysis. Western blotting was done as indicated below (section
2.5.1). For Western analysis of the CoIP samples, primary antibodies used were
monoclonal mouse anti-myc (Upstate) and monoclonal mouse anti-FLAG (Sigma) both
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at 1:5,000 dilution. Secondary antibody used was affinity purified peroxidase-labelled
goat anti-mouse IgG (anti-mouse; Kirkegaard & Perry Laboratories) at 1:10,000 dilution.
2.5.1 SDS-PAGE and Western blotting
Samples were electrophoresed in Ix running buffer (1.44% glycine, 0.303% Tris
and 1% SDS), at 150 volts until the loading dye reached ~1 cm from the bottom of the
gel. Samples were then transferred onto a polyvinylidenefluoride (PVDF) membrane
(Millipore) in transfer buffer (0.303% Tris, 1.44% glycine, 20% methanol) at 100 volts
for 1 hour using a Biorad Mini-Gel apparatus. Membrane was then stained with Ponceau
stain (0.1% Ponceau Red in 5% glacial acetic acid) for 5 minutes and molecular weight
standards were marked with pencil. The Ponceau stain was then removed by washing the
membrane twice in PBS containing 0.2% Tween (PBSt; 8% NaCl, 0.2% KCl, 1.44%
Na2HPO4, 0.24%) KH2PO4, 0.2% Tween (Amresco)), 10 minutes per wash. Blocking was
done for 1 hour using blocking solution (5% skim milk prepared in Ix PBSt). Incubation
with primary and secondary antibodies occurred for 1 hour. The membrane was then
exposed using either 1 ml of enhanced chemiluminescent (ECL) western blotting
detection reagents (GE Healthcare), or to detect weaker signals 500 µ? of high sensitivity
chemiluminescent substrate (Millipore). Between incubation steps, the membrane was
washed twice with PBSt as above. All antibodies were diluted in blocking solution and
all incubations were done at room temperature (RT) with gentle shaking.
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2.6 Gel Filtration
HEK 293T cells were co-transfected as above (section 2.2.1) with pRK5MYC-
sedlin and pFLAGCMV6a-SPATA4 constructs and the appropriate controls. Cells were
prepared and lysed as indicated above (section 2.2). Samples contained 5 mg of lysate
made up to a total volume of 1 ml with gel filtration buffer ( 150 mM NaCl, 50 mM Tris
pH 7.2, 0.5 mM EDTA, 1 mM DTT) and was loaded on a Superdex™ 200 column (GE
Healthcare), where the flow rate was 0.5 ml/min and 0.5 ml fractions were collected.
After fractionation, 25 µ? of each sample was loaded on a SDS-PAGE gel for Western
analysis. Western blotting was done as above (section 2.5.1). Western analysis for gel
filtration employed mouse anti-myc (Sigma) and mouse anti-FLAG antibody (Upstate)
simultaneously at 1:5,000 dilution, followed by anti-mouse at 1:10,000 dilution.
Membrane was exposed as above (section 2.5.1).
2.7 Purification of Recombinant proteins and in vitro Binding Assay
2.7.1 Purification of MBP- and His-tagged proteins
To purify MBP-tagged proteins a modified protocol for purifying soluble fusion
proteins by New England Biolabs was used (pMAL Protein Fusion & Purification System
- Instruction Manual). Cells were grown to an OD60O of 0.5-1.0 at 37°C and protein
production was induced by the addition of 1 mM IPTG with shaking at 250 rpm at 25°C
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overnight. Cells were then pelleted at 4,000 rpm for 20 minutes at 4°C in the Avanti-J251
centrifuge (Beckman Coulter TM). Cell pellets were then resuspended in 25 ml of
column buffer (20 mM Tris-HCl, 200 mM NaCl, 1 mM EDTA, 1 mM DTT) and either
frozen at -800C for future use, or were immediately sonicated for 2 minutes by a series of
non-consecutive 10 second pulses. Lysates were then clarified at 20,000 g for 20 minutes
at 40C and the supernatant (crude extract) collected. The crude extract was then diluted
1:6 with column buffer and then poured onto a disposable 1.5 ? 12 cm column (Biorad)
containing a bed volume of 500 µ? of amylose resin (New England Biolabs) pre-
equilibrated with column buffer. Retained proteins were washed with 5 column volumes
of column buffer before being eluted with 1 1 ml of elution buffer (20 mM Tris-HCl, 200
mM NaCl, 1 mM EDTA, 1 mM DTT, 10 mM maltose (Bioshop)) in 1 ml fractions.
Protein concentration was then assayed using the Biorad Protein Assay dye-reagent as per
manufacturer's instructions. Concentrated protein samples were then pooled together and
passed through a 10 DG column (Biorad) in Ix binding buffer (10 mM HEPES pH 7.4,
25 mM NaCl, 1 15 mM KCl, 2 mM MgCl2, 0.1% Triton X-100) to remove excess maltose
and the protein concentration was redetermined as above.
To purify His-tagged proteins, cells were grown and induced as indicated above.
Cells were pelleted at 4,000 rpm for 30 minutes at 40C in the Avanti -J251 centrifuge
(Beckman Coulter TM). Pellets were then resuspended in 35 ml of lysis buffer for His-
tagged proteins (300 mM NaCl, 50 mM Tris-HCl pH 8.5, 9.7 mM ß-mercaptanol, 0.5%
Glycerol, 0.1 % Triton X-100, 1 mM AEBSF) and sonicated as above. Cell lysates were
then centrifuged at 30,000 g for 30 minutes and crude extract was collected. The crude
extract was then incubated at 4°C on a nutator with 1 ml of Ni-NTA Agarose (Qiagen) to
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allow binding, and then passed through a 1.5 ? 12 cm disposable column. The retained
proteins were then washed twice with 10 ml wash buffer (50 mM Tris-HCl pH 8.5, 300
mM NaCl, 10 mM ß-mercaptanol) before being eluted with 3 ml of imidazole elution
buffer (50 mM Tris pH 8.8, 200 mM NaCl, 200 mM imidazole) in 1 ml fractions. Protein
concentration was then assayed as above.
2.7.2 In vitro Binding Assay
In vitro binding assays contained 0.1 µ? of either MBP or MBP-SPATA4 with
increasing amounts (0, 0.05, 0.1, 0.25 µ?) of a heterotrimeric complex composed of His-
sedlin/TRAPPC3/TRAPPC5 or 0.5 µ? of either MBP or MBP-SPATA4 with increasing
amounts (0, 0.1, 0.2, 0.5 µ?) of N-terminal 6xHis-tagged sedlin (His-sedlin). Note that
in vitro binding assays containing the heterotrimeric complex were also performed using
the latter concentrations, however, using the former concentrations allowed for better
visualization of increased binding of sedlin to SPATA4. Samples were made up to a total
volume of 250 µ? with Ix binding buffer and left on ice at 4°C for 1 hour to allow
binding. Pulldown employed 10 µ? amylose resin (New England Biolabs) on nutator for 1
hour. Samples were washed 3x with 250 µ? of Ix binding buffer, and spun down for 30
seconds at 5,000 rpm. Protein was eluted from the beads by heating to 95°C in 25 µ? of Ix
SB for 2 minutes prior to storage at -200C or loading on a SDS-PAGE gel for Western
analysis. Western blotting was performed as above (section 2.5.1). Western analysis used
affinity purified, polyclonal antibody recognizing sedlin (anti-sedlin) at a dilution of
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1 : 10,000. The secondary antibody used was affinity purified antibody peroxidase-labelled
goat anti-rabbit IgG (anti-rabbit) at 1:10,000 dilution (anti-rabbit; Kirkegaard & Perry
Laboratories). Membrane was exposed as above (section 2.5.1).
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3. Results
3.1 Identification of sedlin interactors using the classic Yeast two-hybrid screen
To study sedlin the Matchmaker™ GAL4 Two-Hybrid System 3 (Clontech),
which is a classic Y2H screen was employed to look for novel interactors of the protein.
This approach was taken because the Y2H is a simple, fast and effective way to
determine novel protein-interactors, which therefore allows for the elucidation of the
function(s) and role(s) of sedlin by knowing the function(s) and role(s) of its interacting
partner(s). The principle behind the Y2H is that two fusion proteins are created that
contain either the BD of the GAL4 transcriptional activator (termed the bait protein), or
the AD of GAL4 (termed the prey protein). When an interaction takes place, GAL4
transcriptional activity is reconstituted as measured by the production of the reporter
genes HIS3, ADE2, MELI and lacZ which allow the production of histidine, adenine, ot-
galactosidase and ß-galactosidase respectively (Figure 3.1).
In this Y2H screen the bait protein contained sedlin fused to the BD (pGBKT7-
sedlin) while the prey proteins were a library of pretransformed human cDNA in the AD
vector (Clontech). Before the screen was conducted, it was necessary to ensure that the
bait protein did not autoactivate the reporter genes. Therefore, approximately 100 cells of
the strain AH 109 containing pGBKT7-sedlin were plated on -TrpAHis solid medium
containing varying concentrations of 3AT (3AT prevents the production of histidine by
inhibiting the His3 protein), where the concentration ranged from 0-60 mM 3AT. By
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repeating this procedure three times it was found that 0.5 mM of 3AT was necessary to
remove any autoactivation of the reporter genes caused by sedlin (Figure 3.2). However,
1 mM of 3AT was used in the actual screen to ensure that autoactivation did not occur.
After mating the library to the query strain (pGBKT7-sedlin) cells were plated on -Trp/-
Leu/-His/-Ade (QDO) solid medium containing X-a-gal, where X-a-gal is a substrate for
a-galactosidase and allows the production of a blue coloration for white/blue screening.
The Y2H screen resulted in hundreds of hits, where the resulting colonies were of various
sizes and varying shades of blue. However, since only the strong interactors of sedlin
were desired only the dark blue colonies were picked for further analysis. This resulted in







Note: The above image was taken from the Matchmaker™ Pretransformed Libraries User Manual.
Figure 3.1: Principle of the Y2H screen. In the classic Y2H screen two fusion proteins
are expressed separately, where one fusion protein is fused to the binding domain (BD) of
the GAL4 transcriptional activator and is called the bait protein while the other is fused to
the activation domain (AD) of GAL4 and is called the prey protein (or the library
protein). Only when the bait and the prey protein physically interact can the transcription
of the reporter genes be activated, which subsequently allows growth on the selective














Figure 3.2: Autoactivation by sedlin is inhibited by 0.5 mM 3AT. Before the Y2H
screen was performed it was found that sedlin (the bait protein) autoactivates the reporter
genes. Therefore, to correct for the autoactivation, -100 cells of the strain AH109
containing pGBKT7-sedlin was plated on several -TrpAHis solid medium containing
various concentrations of 3AT ranging from 0-60 mM 3AT. It was found that 0.5 mM
3AT was the minimum concentration needed to inhibit the autoactivation. The top panel
shows the autoactivation caused by sedlin when the strain AH 109 containing pGBKT7-
sedlin is plated on -TrpAHis solid medium without 3AT, while the bottom panel shows
that in the presence of 0.5 mM 3AT the autoactivation is inhibited as observed by the
appearance ofpinpoint colonies.
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3.2 Analysis of interactors reveals SPATA4 as a novel interactor of sedlin
To begin analyzing the potential sedlin interactors, it was necessary to make sure
that each positive isolate contained only one prey plasmid. If a clone contained more than
one prey plasmid then further analysis on the clone would likely result in confusing data.
Therefore, each clone was first streaked on DDO solid medium containing X-a-gal,
followed by choosing one blue colony and streaking on TDO solid medium containing X-
a-gal. After both streakings a mixture ofblue and white colonies was not observed which
indicated that each positive clone contained only one prey plasmid. Next, colony PCR
was performed on each clone to confirm that each prey plasmid contained an insert. The
latter result showed that the majority of clones did contain an insert since an intense band
of a specific size was observed for all successful amplifications (data not shown). For the
unsuccessful amplifications the PCR was repeated with success (measured as a single
band from the PCR reaction) for all but five colonies. However, although the five clones
did not give an amplification product, it is unlikely that an insert is not present since the
clones are able to grow on DDO and TDO solid medium which indicates that an
interaction between the bait and prey protein is present. Most likely the five clones that
were unamplified require very specific amplification settings that were not met in the
general settings used for the rest of the clones.
In an attempt to detect the presence of inserts represented multiple times in the
screen, and thus obtain a reliable estimation for the number of sedlin interactors obtained
using the Y2H screen, an AIuI digest was performed on the amplified products. AM was
chosen as the restriction enzyme since it is known to be a frequent cutter recognizing the
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sequence AGCT. From the resulting digestion patterns (data not shown), inserts were
grouped together and were thought to represent identical inserts. However, after
sequencing it was discovered that not all inserts within a group represented the same
insert. This mistake most likely arose due to human error, since the digestion patterns
were analyzed by eye and thus subtle differences in the digestion patterns of unique
inserts may have escaped notice. Nonetheless, this method removed 1 5 duplicates from
the list of sedlin interactors and thus 169 hits remained for further analysis (Table 3.1).
As the former approach was unable to give a reliable estimation of the number of
unique sedlin interactors that were obtained from the Y2H, prey plasmids were rescued
from the positive clones and retransformed into an AH 109 strain containing either
pGBKT7-sedlin or pGBKT7, where the former transformation served to reconfirm the
interaction between sedlin and its interacting partner and the latter served as a control and
allowed for the removal of false-positives (prey proteins that autoactivate the reporter
genes). Thus, the rescue and subsequent transformation of prey plasmids narrowed down
the list of sedlin interactors and allowed for only reconfirmed sedlin interactors to be sent
for sequencing. The transformation of prey plasmids was also done in an AH 109 strain
containing pGBKT7-TRAPPC2L since C2L is a sedlin-like protein and is hypothesized
to functionally compensate for mutated sedlin in SEDT patients (Scrivens et al., 2009).
Therefore, it was of interest to see whether proteins that interacted with sedlin also
interacted with C2L. The transformation of prey plasmids into the strain AH 109
containing pGBKT7-sedlin was performed for all hits, however only 53 transformations
were successful. The inability to transform the remaining 1 16 prey plasmids is thought to
be due to an unsuccessful rescue of the corresponding prey plasmids from the original
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colonies. Of the 53 transformations, 34 were observed not to interact with sedlin, 10 were
false positives, while 9 were reconfirmed as sedlin interactors. It is unknown why some
of the hits were not reconfirmed. Sequencing of the 9 sedlin interactors revealed that 2
were contigs while 1 was out of frame (presumably resulting in a non-specific
interaction), leaving 6 sedlin interactors (Table 3.2 and Figure 3.3). Of the 6 sedlin
interactors, one was found to be TRAPPC3 which was previously identified as a sedlin
interactor (Kim et al., 2006). This latter result increases the confidence in the 6
reconfirmed sedlin interactors.
To better characterize the function(s) and role(s) of sedlin, efforts were focused
on one novel sedlin interactor called SPATA4. We decided to characterize the interaction
between sedlin and SPATA4 since SPATA4 was found to interact with sedlin but not
with C2L. This observation was interesting because thus far, all the proteins that
interacted with sedlin also interacted with C2L. Therefore, this indicates that the
interaction of SPATA4 with sedlin is specific and suggests that sedlin contains at least
one unique function that cannot be carried out by C2L.
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Table 3.1: Sequenced prey inserts obtained from sedlin Y2H screen
Clone No. Gene
CDC7 - homo sapiens cell





chromosome 1 0 genomic
contig, alternate assembly NW 001838014.1
30
PRKRIR (DAP4; P52rIPK;
MGC 102750) - protein-kinase,
interferon-inducible double
stranded RNA dependent
inhibitor, repressor of (P58
repressor) NM 004705.2
34
NEK2 - NIMA (Never in
mitosis gene a) - related kinase
2 NM 002497.2
40
_-- Homo sapiens chromosome
8,cloneRPll-713M15




42 (47) NM 000655.3
44
FKBP3 - FKBP3 binding
protein 3, 25 kDa NM 002013.2
REPS2 (POBl; REPS2) -
RALBPl associated Eps
domain containing 250 NM 001980975.1
59
POLR2G - polymerase (RNA)
II (DNA directed) polypeptide NM 002696.1
60 (67)
PTGER3 - Prostaglandin E.
receptor 3 (subtype EP3) NM 198719.1
63
- - Homo sapiens
chromosome 12 genomic
contig, alternate assembly NW 001838063.1
64
(112, 113)
POSTN - periostin, osteoblast
specific factor NM 006475.1
69(111)
SPATA22 - spermatogenesis
associated 22 NM 032598.3
78
ALDHlAl (ALDC; ALDHl;
PUMB 1 ; ALDH 1 1 ; RALDH 1 ;
ALDH-El; MGC23 18;
ALDHlAl) -aldehyde





chromosome 6 genomic contig,
alternate assembly NW 001838990.2
82
_- - Homo sapiens
chromosome 7 genomic contig,
reference assembly NT 007819.16
83
ARID2 - AT rich interactive
domain 2 (ARID, RFX-like) NM 152641.2
88(12)
SPATA4 - spermatogenesis
associated 4 NM 144644.2
89 (90)
POLR3H - polymerase (RNA)









TRAPPC3 - homo sapiens
trafficking protein particle
complex 3 NM 014408.3
95 FOXN3 - forkhead box N3 NM 001085471.1
102 (33)
LRRTM3 - leucine rich repeat




component, homolog NM 015471.3
130
LAP3 - Homo sapiens leucine




oncogene homolog NM 002467.3
142
FAM47E - family with
sequence similarity 47,
member E (Homo sapiens
similar to genethonin 1 ,
transcript variant) XM 001720938.1
143 (79)
HS6 - homosapiens
chromosome 6 genomic contig,
reference assembly NT 007299.12
144
NRBF2 - Homo sapiens
nuclear receptor binding factor NM 030759.3
48
2 (mRNA)
ASXLl - additional sex combs
146 like 1 (Drosophila) NM 015338.4 1
DLGAP5 - homo sapiens discs,
large homolog 7 (Alias:
148 HURP) NMO 14750.3 1
SPOP - speckle-type POZ
154 protein NM 003563.3 1
NUP 155 - nucleoporin 155
162 I kDa 1 NM_1 53485.1 | 1
Note: In total there are 1 84 clones obtained from the Y2H screen, however only the sequenced colonies
were included in the table.
Table 3.1: Sequenced prey inserts obtained from sedlin Y2H screen. In an attempt to
estimate the number of unique interactors obtained from the sedlin Y2H screen all 184
hits were amplified and subsequently digested with AIuI. Similar digestion patterns were
then grouped together and were assumed to represent the same insert. Sequencing of a
few groups revealed that within a group not all inserts were identical. This table provides
a complete list of all the sequenced inserts along with their corresponding accession
number. The corresponding clone number is also provided, where clone numbers within
parenthesis indicate clones containing identical inserts.
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LAP3 - Homo sapiens leucine aminopeptidase
3, mRNA NM 015907.2
50
REPS2 (POBl; REPS2) - PvALBPl associated
Eps domain containing 2 NM 001980975.1
64(112,113) POSTN - periostin, osteoblast specific factor NM 006475.1
69(111) SPATA22 - spermatogenesis associated 22 NM 032598.3
88(12) SPATA4 - spermatogenesis associated 4 NM 144644.2
94
TRAPPC3 - homo sapiens trafficking protein
particle complex 3 NM 014408.3
63
- - Homo sapiens chromosome 12 genomic
contig, alternate assembly NW 001838063.1
82
_- - Homo sapiens chromosome 7 genomic
contig, reference assembly NT 007819.16
78
ALDHlAl (ALDC; ALDHl; PUMBl;
ALDHIl; RALDHl; ALDH-El; MGC2318;
ALDHlAl) - aldehyde dehydrogenase 1 family,
member Al NM 000689.3
False Positives
30
PRKRIR (DAP4; P52rIPK; MGC 102750) -
protein-kinase, interferon-inducible double
stranded RNA dependent inhibitor, repressor of
(P5 8 repressor) NM 004705.2
93
(15,29,167,
175, 153) ZNF350 - zinc finger protein 350 NM 021632.3
102 (33)
LRRTM3 - leucine rich repeat transmembrane






_- - Homo sapiens chromosome 10 genomic













Table 3.2: Summary of Potential Interactors, False Positives and Non-Interactors of
Sedlin. Prey plasmids were rescued from positive clones and transformed into the yeast
strain AH 109 containing either pGBKT7-sedlin or pGBKT7, where the former
transformation serves to reconfirm the interaction with sedlin and the latter serves to
remove false positives (prey proteins that autoactivate the reporter genes). Cells were
plated on DDO solid medium to confirm the presence of the bait and prey plasmids and
were also plated on TDO solid medium containing 1 mM 3AT to detect the interaction
between the bait and prey proteins. The above table classifies the results of the
transformations as either containing a potential interactor if the interaction was
reconfirmed, false positive if the prey protein autoactivates the reporter genes or non-
interactor of sedlin if the interaction was not reconfirmed. Out of 53 successful
transformations, 9 were classified as potential interactors, 10 as false positives and 34 as
non-interactors of sedlin. Subsequent to the sequencing of the 9 potential interactors a
total oí 3 hits were disqualified since 2 inserts were contigs while the remaining insert
was out of frame. The hits that were removed as potential interactors are indicated in
italicize;? font.
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Figure 3.3: Sedlin interactors obtained from Y2H screen. Prey plasmids were rescued
from positive clones and transformed into the yeast strain AH 109 containing either
pGBKT7-sedlin, pGBKT7-TRAPPC2L or pGBKT7. Cells were grown to an OD600 of 1.0
and plated on DDO, TDO and QDO solid medium to show respectively, the presence of
both plasmids and the interaction between the bait and prey protein under medium and
high stringency conditions. The TDO and QDO solid medium both reveal that SPATA4
interacts with sedlin but not with C2L. The negative interactor is clone 149 from the Y2H
screen, however the identity is not known since it was not sent for sequencing.
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3.3 Bioinformatic analysis of SPATA4
To ensure that the SPATA4 Y2H insert accurately represents SPATA4, the prey
vector, pGADT7-SPATA4, was sequenced. Sequencing revealed the presence of a few
mutations within the nucleotide sequence (Figure 3.4A) and consequently within the
peptide sequence of SPATA4 (Figure 3.4B). In the nucleotide sequence, a silent
mutation, an insertion mutation resulting in a frameshift, and a deletion mutation shortly
thereafter were detected. The protein sequence of SPATA4 was observed to be nearly
identical to the actual SPATA4 sequence with the exception of the presence of short
peptide sequences at the beginning and the end of the translated protein, where the former
is due to translation of the 5' untranslated region while the latter is due to the frame shift
mutation. Furthermore, the frame shift causes a premature termination of the SPATA4
protein and results in the absence of 38 residues from the C-terminus. These results
suggest that the extreme carboxy-terminus of SPATA4 is not involved in its interaction
with sedlin.
SPATA4 is a relatively novel protein and as such not much is known concerning
the cellular function(s) that SPATA4 may play. To characterize SPATA4 a
bioinformatics analysis was performed. A phylogenetic tree of SPATA4 across thirteen
different species (Figure 3.5A) reveals that SPATA4 from Homo sapiens is more closely
conserved in orthologues from primates and more divergent when compared to
orthologues found in aquatic species and Gallus gallas (chicken). The latter observation
is better seen in Table 3.3 where the percent identity of SPATA4 across the thirteen
different species is given. The table also reveals that among species, SPATA4 ranges
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from 39-99% identity which indicates a fairly high degree of conservation throughout
evolution, and moreover suggests a conserved importance for SPATA4. A multiple
sequence alignment of SPATA4 from eight different species was also performed (Figure
3.5B). The alignment revealed that the majority of conserved residues are in the middle
of the protein sequence which, as determined by Conserved Domains (NCBI) is where a
domain of unknown function (DUF 1042) is located. The DUF 1042 domain of SPATA4
spans from residues 55-211. In an attempt to learn more about SPATA4 and the
DUF 1042 domain, a BLAST search within the human genome was performed using the
DUF 1042 sequence from SPATA4 as the query. The search found two proteins called
SPEFl and SPEF2 (sperm flagellar 1 and 2, respectively). Interestingly, the latter
proteins are also implicated in spermatogenesis (Chan S.W. et al., 2005; Sironen et al.,
2006). A multiple sequence alignment of the three DUF 1042 domains revealed fourteen
identically conserved residues that lay within a calponin homology (CH) domain as
determined by Conserved Domains (NCBI) (Figure 3.5C).
In an effort to examine the expression profile of SPATA4 Genecards
(http://www.genecards.org) was used. While an electronic Northern (Figure 3.5D middle
panel) and the literature on SPATA4 suggest a testis-specific expression pattern,




















Figure 3.4: Sequence analysis of SPATA4 from Y2H library. A) Nucleotide sequence
of SPATA4 insert from Pretransformed Normalized Matchmatker™ Human
Universal cDNA Library. Sequencing of the prey vector, pGADT7-SPATA4, revealed
the presence of a few mutations in the nucleotide sequence of SPATA4. Highlighted in
purple is a silent mutation of A to G, highlighted in red is the insertion of a T and
subsequently a frame shift for downstream codons, highlighted in blue indicates the
deletion of a G nucleotide immediately following the highlighted nucleotide and
subsequently indicates the end of the frame shift. Italicized nucleotides indicate the extra
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G' s added to the insert by the reverse transcriptase used to make the library, the blue font
is the sequence corresponding to the coding sequence (CDS) of SPATA4, and the black
font at the beginning and end of the sequence correspond to the 5' and 3' untranslated
regions, respectively. B) Protein sequence of SPATA4 insert from Pretransformed
Normalized Matchmaker™ Human Universal cDNA Library. Blue font corresponds
to residues identical to the protein sequence of SPATA4. Highlighted in red are residues
that are not part of the SPATA4 protein: the first highlighted portion corresponds to the
translation of the 5' untranslated region, while the second highlighted portion
corresponds to the frame shift caused by the insertion of a T nucleotide. Also note that
the insertion causes the premature termination of the SPATA4 protein, where the above
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Figure 3.5: Bioinformatic analysis of SPATA4 (Homo sapiens). A) Phylogenetic tree
of SPATA4. The phylogenetic tree for SPATA4 was made using the free software
program ClustalW and contains thirteen SPATA4 homologues. The accession numbers
are: Bos Taurus: NPJ)OlOl 1677.1; Canis lupus familiaris: XP_851298; Ciona
intestinalis: NP_001 029005.1; Danio rerio: NPOO 10040 13.1; Equus caballus:
XP_001493059; Gallus gallus: NPJ)0 1026309.1; Homo sapiens: NP653245.2; Macaca
fascicularis: BAE01 027.1; Macaca mulatta: NPOO 1030604.1; Mus musculus:
NP_598472.2; Oncorhynchus mykiss: NP0011 17998.1; Pan troglodytes:
NP_001008990.1; Rattus norvegicus: NP00 1002852.1. The asterisk indicates the
species used in the multiple sequence alignment (B) of SPATA4. B) Multiple sequence
alignment of SPATA4. A multiple sequence alignment of eight of the thirteen SPATA4
homologues was performed using ClustalW and conserved residues were highlighted
using Boxshade. The black, dark grey and light grey shading represent residues that
display 100% identity, at least 70% identity and at least 70% similarity, respectively. The
underlined region indicates the position of the DUF 1042 domain which spans from
residue 55-211 in Homo sapiens. Note that eight sequences were used in the multiple
alignment as only one representative sequence was taken from each order of organisms.
Also note that the selection of the representative sequence for the various orders was
randomly selected. C) Mulitple sequence alignment of the DUFl 042 domain of
SPATA4, SPEFl and SPEF2. Analysis of Homo sapiens DUF 1042 domains from three
proteins by ClustalW and Boxshade (as performed above) revealed the presence of 14
residues that display 100% identity, which are indicated by black shading. The dark grey
and the light grey shading represent residues that display at least 60% identity and at least
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60% similarity, respectively. The underlined region represents the calponin homology
(CH) region that spans approximately the first one hundred residues in the DUF 1042
domain. D) Electronic expression of SPATA4. Using Genecards, SPATA4 is found to
be widely expressed both experimentally (top panel, microarray) and electronically
(lower two panels). However, note that although the experimental expression of SPATA4
by Genecards indicates that SPATA4 was not detected in testis, other studies have shown
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3.4 In vivo coimmunoprecipitation of SPATA4 and sedlin
To begin characterizing the interaction between sedlin and SPATA4 a
coimmunoprecipitation (CoIP) was performed. All experiments from this point onwards
were performed with SPATA4 and sedlin from mouse. The CoIP was performed using
lysates prepared from HEK 293T cells co-transfected with plasmids expressing myc-
sedlin and FLAG-SPATA4. Sedlin and its binding partner were immunoprecipitated
using rabbit anti-myc antibody, and the Western probed using mouse anti-myc antibody
and mouse anti-FLAG antibody either simultaneously or separately. Both probing
methods revealed that sedlin and SPATA4 do interact in mammalian cells under in vivo
conditions (Figure 3.6A). Furthermore, it was seen that the expression of SPATA4 is
stabilized by the co-expression of sedlin since a stronger band for SPATA4 was
consistently observed when sedlin was present as compared to when SPATA4 was
expressed alone. This latter observation further supports an interaction between sedlin
and SPATA4.
Given that the interaction between sedlin and SPATA4 was detected using
mammalian cells, and given that sedlin and C2L are components of the same protein
complex, it was investigated whether SPATA4 interacts with C2L in mammalian cells.
To this end another CoIP was performed as above except lysates were prepared from
HEK 293T cells co-transfected with plasmids expressing myc-TRAPPC2L and FLAG-
SPATA4. Western analysis was also done as above. In mammalian cells and under in
vivo conditions, an interaction between C2L and SPATA4 was observed (Figure 3.6B).
Furthermore, SPATA4 also appeared to be stabilized by the presence of C2L. Taken
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together with the Y2H results, the CoIP experiments are consistent with an interaction
between SPATA4 and TRAPP mediated by the sedlin protein.
In view of the fact that SPATA4 was shown to interact with both sedlin and C2L,
we wanted to show that the latter interactions were specific and that SPATA4 is not a
promiscuous binding protein. To this end another CoIP was performed as above using
myc-ECT2 (421-883 aa) in place of either myc-sedlin or myc-TRAPPC2L, and the
Western was also done as above. The epithelial cell transforming sequence 2 (ECT2) is a
member of the DbI family of guanine nucleotide exchange factor for Rho GTPases and is
required for cytokinesis. An interaction was not observed between ECT2 (421-883 aa)
and SPATA4 suggesting that the interaction between sedlin and SPATA4, and C2L and
SPATA4 is specific (Figure 3.6C). Additionally, because the co-expression of myc-ECT2
(421-883 aa) with FLAG-SPATA4 was not seen to stabilize the expression of SPATA4
to the extent that either sedlin or C2L stabilized SPATA4, this further supports the notion
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Figure 3.6: SPATA4 coimmunoprecipitates with both sedlin and C2L in HEK 293T
cell lysates. Lysates were prepared from HEK 293T cells co-transfected with plasmids
expressing: A) Lanes 1 and 4: FLAG-SPATA4 with myc-sedlin; Lanes 2 and 5: FLAG-
SPATA4 with pRK5MYC; Lanes 3 and 6: pFLAGCMV6a with myc-sedlin; B) Lanes 1
and 3: FLAG-SPATA4 with myc-TRAPPC2L; Lanes 2 and 4: pFLAGCMV6a with myc-
TRAPPC2L; C) Lanes 1 and 3: FLAG-SPATA4 with myc-ECT2 (421-883 aa); Lanes 2
and 4: pFLAGCMV6a with myc-ECT2 (421-883 aa). Samples were immunoprecipitated
with 2 µg of rabbit anti-sedlin (panel A) or rabbit anti-myc (panels B and C) IgG on ice at
4°C for 16 hours, followed by incubation with 10 µ? of Protein ?-agarose on a nutator at
4°C for 2 hours. Samples were analyzed by Western blotting using mouse anti-myc and
mouse anti-FLAG simultaneously both at a 1:5,000 dilution. Secondary antibody used
was affinity purified peroxidase-labelled goat anti -mouse IgG at 1:10,000 dilution.
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FLAG-SPATA4 is -36 kDa, myc-sedlin is ~ 16 kDa and myc-ECT2 (421-883 aa) is ~ 53
kDa. Boxed panel shows lanes 3 and 4 CoIP samples at longer exposure time, t=4
minutes (compared to t=30 seconds for the corresponding CoIP samples). Even at t=4
minutes there is no sign of SPATA4 interacting with ECT2.
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3.5 Gel Filtration of HEK 293T lysates reveals SPATA4 co-fractionates with
assembled TRAPP complex
The CoIP results above suggested that SPATA4 binds to the TRAPP complex.
When mammalian cell lysates are fractionated by size exclusion chromatography sedlin
appears in two fractions: a high molecular weight fraction and a low molecular weight
fraction. The former represents the TRAPP complex while the latter represents
monomeric sedlin (Sacher and Ferro-Novick, 2001; Yamasaki et al., 2009). To examine
which form of sedlin SPATA4 binds to, lysates from HEK 293T cells co-transfected with
plasmids expressing myc-sedlin and FLAG-SPATA4 were fractionated by size exclusion
chromatography. The resulting fractions were then analyzed by Western blotting using
mouse anti-myc and mouse anti-FLAG. It was observed that sedlin is found in both the
high and the low molecular weight fractions, consistent with previous findings. It was
also found that SPATA4 co-fractionates with sedlin only in the high molecular weight
fractions (Figure 3.7A) suggesting that SPATA4 physically interacts with TRAPP. The
fact that SPATA4 was not observed to fractionate with sedlin in the low molecular
weight fractions suggests that SPATA4 may not directly interact with sedlin, or that
SPATA4 requires additional components to promote and stabilize the interaction between
sedlin and SPATA4.
In addition, cell lysates of HEK 293T cells co-transfected with FLAGCMVóa and
myc-sedlin or with FLAG-SPATA4 and pRK5MYC were prepared as above. When
expressed on its own, myc-sedlin showed the expected results where sedlin was found to
fractionate with both the high and the low molecular weight fractions (Figure 3.7B)
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representing TRAPP and monomeric sedlin, respectively. Overexpression of only
SPATA4 showed a weak band that co-fractionated with the TRAPP complex. This weak
expression of SPATA4 in the absence of co-expressed sedlin is consistent with previous
findings (refer to section 3.4) and further supports the notion that the presence of sedlin
has a stabilizing effect on SPATA4 expression (Figure 3.7C). Taken together with the in






































Figure 3.7: Gel Filtration showing SPATA4 physically interacts with TRAPP.
Lysates were prepared from HEK 293T cells co-transfected with plasmids expressing: A)
FLAG-SPATA4 with myc-sedlin; B) pFLAGCMV6a with myc-sedlin; C) FLAG-
SPATA4 with pRK5MYC. Lysates were fractionated on a Superdex™ 200 column and
0.5 ml fractions were collected. Fractions were analyzed by Western blotting using
mouse anti-myc and mouse anti-FLAG simultaneously at a 1:5,000 dilution, followed by
affinity purified antibody peroxidase-labelled goat anti-mouse IgG at a 1:10,000 dilution.
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FLAG-SPATA4 is -36 kDa and myc-sedlin is -16 kDa. In Panel C the * marks the faint
bands observed when FLAG-SPATA4 is not co-expressed with myc-sedlin. The top
panel of the inset represents a repeat of the transfection performed in (C) to better show
the SPATA4 bands, while the bottom panel shows the background bands that appear for
untransfected HEK 293T cells. Note that the membranes in panels (A), (B) and (C) were
exposed for 6 minutes while the membrane in the inset panels were exposed for 30
seconds.
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3.6 In vitro binding assay suggests SPATA4 binds to sedlin in the TRAPP
complex
It has previously been shown that sedlin in the monomelic form has minor
structural differences compared to sedlin in the TRAPP complex (Kim et al., 2006; Jang
et al., 2002b; Jang et al., 2002a) (Figure 3.8). To support the notion that SPATA4 binds
to TRAPP and not monomeric sedlin as suggested by the gel filtration experiment above,
an in vitro binding assay was performed using sedlin in its monomeric form as well as
sedlin bound to its TRAPP partners TRAPPC3 and TRAPPC5. The proteins were
purified from bacterial cell lysates expressing either MBP, MBP-SPATA4, His-sedlin or
His-sedlin/TRAPPC3/TRAPPC5. Using His-sedlin, the binding assay samples contained
0.5 µ? of either MBP or MBP-SPATA4 with increasing amounts (0, 0.1, 0.2, 0.5 µ?) of
His-sedlin. Consistent with the gel filtration result above, we could not detect an
interaction between monomeric sedlin and SPATA4 as no increased binding of sedlin
was detected when MBP-SPATA4 was used compared to MBP alone (Figure 3.9A). In
contrast to monomeric sedlin, SPATA4 bound very efficiently to sedlin in the
heterotrimeric complex of His-sedlin/TRAPPC3/TRAPPC5 (Figure 3.9B). The binding
was so efficient that the concentrations of MBP, MBP-SPATA4 and the heterotrimeric
complex were respectively reduced to 0.1 µ? (former two proteins) and 0, 0.05, 0.1, 0.25
µ? (latter proteins). These results support the notion that SPATA4 binds to TRAPP and
not to monomeric sedlin. Therefore, the function of SPATA4 is likely carried out within








Figure 3.8: Overlay of sedlin in the heterotrimeric and monomeric state. When
sedlin is in the heterotrimeric complex His-sedlin/TRAPPC3/TRAPPC5, sedlin contains
6.5 turns (dark blue) in the N-terminal a-helix compared to 4 turns when it is in the
monomeric state (cyan). The above overlay shows that the additional turns are found at
the beginning (bottom) and the end (top) of the N-terminal helix at residues 31-34 and
51-55, which correspond to the sequences KDDH and ENMWL, respectively.
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A f***** «»«ß1· * ,m* - His-sedlin
B «sr#» «p» - His-sedlin
Figure 3.9: In vitro pulldown assays. MBP, MBP-SPATA4, a heterotrimeric His-
sedlin/TRAPPC3/TRAPPC5 complex and His-sedlin were subjected to in vitro binding
assay. In vitro assays contained either A) 0.5 µ? of MBP or MBP-SPATA4 with
increasing amounts of His-sedlin: 0, 0.1, 0.2, 0.5 µ? or B) 0.1 µ? of MBP or MBP-
SPATA4 with increasing amounts of the heterotrimeric complex: 0, 0.05, 0.1, 0.25 µ?.
(Note that lower protein concentrations were used in B) in order to better observe the
increased binding corresponding to increasing concentrations of sedlin.) Samples were
allowed to bind for 1 hour at 4°C and pulldown employed 10 µ? of amylose resin on a
nutator for 1 hour at 40C. Western analysis used affinity purified, polyclonal antibody
recognizing sedlin at a dilution of 1 : 1 0,000 and affinity purified antibody peroxidase-
labelled goat anti -rabbit IgG at 1:10,000 dilution. His-sedlin is ~ 16 kDa.
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3.7 Mutations in sedlin do not affect the interaction with SPATA4
In light of the fact that over 30 different mutations in sedlin are known to cause
the genetic skeletal disorder, SEDT (Savarirayan et al., 2003; Gecz et al., 2003), it was of
interest to determine if mutations in sedlin affected the interaction with SPATA4.
Perhaps mutations in sedlin affect sedlin' s ability to properly interact with specific
proteins, which would thus affect its ability to perform its function(s) within the cell.
Subsequently, the inability of sedlin to perform its function(s) would trigger a cascade of
events that would eventually result in SEDT. To this end, a yeast transformation was
performed that introduced pGADT7-SPATA4 into an AH 109 strain that contained
pGBKT7-sedlin (D47Y), where the former plasmid is the prey plasmid containing
SPATA4 that was rescued from the Y2H screen and the latter is the bait plasmid
containing sedlin with a missense mutation at residue 47. The D47Y mutation in sedlin is
significant because this mutation is one of the several documented missense mutations
that is known to cause SEDT. After the transformation the cells were plated on DDO and
TDO solid medium, where the TDO solid medium contained 1 mM of 3AT, and growth
was observed on both plates. To better analyze the growth, three colonies were picked
from the TDO solid medium and streaked on DDO solid medium to clean up the cells.
One colony from each of the three streaks was subsequently grown and serial dilutions
were spotted onto DDO and TDO solid medium. Growth on the DDO solid medium
confirmed that all colonies contained both plasmids, while growth on the TDO solid
medium indicated that the interaction between sedlin (D47Y) and SPATA4 was still
present (Figure 3.10). Additionally, since the observed growth of AH 109 cells containing
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pGBKT7-sedlin (D47Y) with pGADT7-SPATA4 cells is comparable to the positive
control (AH 109 containing pGBKT7-sedlin and pGADT7-SPATA4), it does not appear
that the interaction is either negatively or positively affected by the D47Y mutation in
sedlin.
Since we were interested in determining if mutations in sedlin had an affect on its
interaction with SPATA4, we did a second yeast transformation where pGADT7-
SPATA4 was transformed into an AH 109 strain containing pGBKT7-sedlin (APA). The
latter sedlin mutation is not one of the mutations that lead to SEDT, however this
mutation replaces the NPF motif of sedlin, where the NPF motif has been shown to
mediate protein-protein interactions, more commonly by interaction with the epsin
homology (EH) domain of various proteins (de Beer et al., 2000). The yeast
transformation and spotting was performed as above and it was observed that the APA
mutation of sedlin neither positively nor negatively affected the interaction with SPATA4
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Figure 3.10: Mutations in sedlin do not affect the interaction with SPATA4. The
yeast strain AH 109 containing either pGBKT7-sedlin (D47Y) or pGBKT7-sedlin (APA)
was transformed with the prey plasmid, pGADT7-SPATA4. Cells were grown on DDO
and TDO solid medium and subsequent to colony growth, three colonies were chosen
from the TDO solid medium and streaked on DDO solid medium. One colony from each
of the three cleaned up streaks was then grown to an OD6oo of 0.9 whereupon serial
dilutions of 1/10, 1/100 and 1/1000 were made. The original and the diluted cultures were
plated on DDO and TDO solid medium, where the left most column is the undiluted
culture and the right most column is the most diluted. Looking at the TDO solid medium
the interaction between both mutated forms of sedlin and SPATA4 appears unaffected as
compared to the interaction observed in the positive control, which is the yeast strain
AH 109 containing pGBKT7-sedlin and pGADT7-SPATA4. The negative control is the
yeast strain AH 109 containing pGBKT7-TRAPPC2L with pGADT7-SPATA4.
4. Discussion
4.1 Sedlin and SPATA4 physically interact
This study describes a novel interaction between the TRAPP subunit sedlin and an
uncharacterized protein called SPATA4. The gene encoding SPATA4 was discovered
during a search for candidate apoptosis-related genes in mouse germ cells (Jiang et al.,
2001). Thus far, very little is known about the SPATA4 protein. However, because
SPATA4 is predominantly expressed in the testes (with the exception of rainbow trout
and zebra fish in which SPATA4 is also found in the ovaries (Liu et al., 2005a; Liu et al.,
2005b), it is thought to play a role in spermatogenesis and in the development of adult
testes. Additionally, further support for this notion comes from gene expression studies
that have found SPATA4 expression to be age dependent; SPATA4 is only expressed at
sexual maturity and expression steadily increases with age whereupon when a certain age
is reached the expression level remains constant (Liu et al., 2004a; Xie et al., 2007).
Furthermore, SPATA4 appears to be an important protein in eukaryotes as it is conserved
between human, rat, rainbow trout, zebra fish, chicken, chimpanzee, macaque, cow and
ascidian (Liu et al., 2005c; Xie et al., 2007).
Using sedlin as the bait protein in a yeast two-hybrid screen, SPATA4 was
obtained and selected for further characterization as SPATA4 showed specific interaction
with sedlin but not with the sedlin-like protein TRAPPC2L (further detail concerning the
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latter interaction is given in section 4.2). SPATA4 co-fractionates with the higher
molecular weight TRAPP complex suggesting that it may bind to sedlin in the complex.
Consistent with this notion, an in vitro pulldown assay revealed that the interaction of
sedlin with SPATA4 may be enhanced and/or stabilized by the presence of sedlin's
neighbouring TRAPP partners, TRAPPC3 and TRAPPC5. The observed increase in
interaction may perhaps be explained by the fact that sedlin undergoes subtle
conformational changes when in complex with TRAPPC3 and TRAPPC5 (Kim et al.,
2006) compared to sedlin in the monomelic state (Jang et al., 2002a). In the monomelic
state sedlin is composed of a mix of a-helices and one ß-sheet, where the ß-sheet
(composed of five antiparallel ß-strands) is sandwiched between an N-terminal a-helix on
one side and two C-terminal anti-parallel a-helices on the other. In the heterotrimeric
state, the overall structure of sedlin remains unchanged. However, the N-terminal a-helix
of sedlin gains an additional 2.5 turns and thus contains 6.5 turns total. Perhaps it is the
presence of the additional 2.5 turns that exposes amino acids and increases the specificity
and binding of sedlin to SPATA4, and/or perhaps specific TRAPPC3 and/or TRAPPC5
residues also contribute to the binding. Crystallization of SPATA4 in complex with the
heterotrimeric complex, His-sedlin/TRAPPC3/TRAPPC5 may provide insight into which
residues and which TRAPP subunits participate in the interaction between sedlin and
SPATA4. Moreover, crystallization may also reveal additional and/or confirm sedlin
residues hypothesized to participate in protein-protein interactions and may further our
understanding of sedlin's function in membrane trafficking and in the TRAPP complex.
From the above studies it is clear that sedlin and SPATA4 do indeed interact.
However, the function that the two perform together is not yet apparent (hypothesized
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fonctions are discussed below in sections 4.3 and 4.4). One way to study the fonction(s)
of the two proteins is to perform localization studies using mammalian cells. By
determining where the two proteins co-localize insight may be gained concerning where
and how the two proteins fonction within a given cell. Studies have revealed that sedlin is
found in the cytoplasm and at the Golgi (Sacher and Ferro-Novick, 2001; Yamasaki et
al., 2009). Localization studies on overexpressed SPATA4 have found that SPATA4
localizes to the nucleus in COS-7 cells (Liu et al., 2004b). Although separately the two
proteins appear to localize to different cellular compartments, small amounts of SPATA4
or sedlin may be in other cellular compartments. It would also be interesting to use
sedlin-null mice and follow the expression pattern of SPATA4 with time as studies have
shown that the expression of SPATA4 commences at the age of sexual maturity and
increases with age (Liu et al., 2004a; Xie et al., 2007). Perhaps in sedlin-null mice, a
decreased expression level of SPATA4 would be observed due to a lack of protein
stability caused by the absence of sedlin. Alternatively, given that there is evidence of
sedlin acting as a transcription factor (Ghosh et al., 2001) the reduced SPATA4
expression may be a result of reduced transcription levels of SPATA4.
4.2 TRAPPC2L interacts with SPATA4 via the TRAPP complex
TRAPPC2L is a novel sedlin-like protein that is hypothesized to compensate for
the function of sedlin in SEDT patients (Scrivens et al., 2009). Therefore it was of
interest to determine if C2L physically interacted with SPATA4. If C2L and SPATA4
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interact then that would suggest the ability of C2L to compensate for sedlin in SEDT.
However, if there is no interaction then that does not necessarily indicate the inability of
C2L to compensate for sedlin. Rather, the latter occurrence may simply suggest that C2L
is not able to fully compensate for sedlin, which may contribute to the explanation of why
the SEDT phenotype is not as severe as expected given that sedlin is ubiquitously
expressed (Scrivens et al., 2009). In this study the Y2H screen revealed that SPATA4
does not physically interact with C2L. However, the CoIP experiment revealed that C2L
is able to immunoprecipitate SPATA4. These results suggest that C2L and SPATA4
interact via the TRAPP complex, where the physical interaction occurs between sedlin
and SPATA4. The ability of C2L to immunoprecipitate, but not directly interact with,
SPATA4 is consistent with a previous finding that showed that C2L and sedlin are part of
the same TRAPP complex (Scrivens et al., 2009). In addition, the lack of physical
interaction between SPATÀ4 and C2L provides support for a conserved functional
divergence between C2L and sedlin. It will ultimately be of interest to determine what
region of sedlin is responsible for the binding to SPATA4 and to determine if the same
region is conserved within C2L. If the region is conserved, it would suggest that other
factors such as TRAPPC3 and TRAPPC5 also participate in the interaction between
sedlin and SPATA4 to promote and/or stabilize the binding since C2L is unable to
physically bind SPATA4. A conserved region between the two proteins would also
suggest residues important for any conserved function(s), folding, and/or binding that
sedlin and C2L may share.
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4.3 Implications in membrane trafficking
As previously mentioned, SPATA4 is an uncharacterized protein that has been
suggested to have a function in spermatogenesis and gonad formation since several
studies have found that it is predominantly expressed in the testis and that the expression
level of SPATA4 appears to correlate with sexual maturity. To date, there has been no
report for the involvement of SPATA4 in membrane trafficking. However, in light of the
novel interaction between sedlin and SPATA4 and the data presented below, this study
proposes that SPATA4 may be involved in membrane trafficking. A bioinformatic
analysis of SPATA4 revealed that it contains a DUF 1042 domain, and that within the
human genome this domain is found in two other proteins. In SPATA4 the DUF 1042
domain makes up -50% of the protein. Of the two proteins that contain the DUF 1042
domain one protein, SPEFl, was shown to bind to ZBEDl. Interestingly, ZBEDl was
found to bind to sedlin by Y2H. It is tempting to speculate that, if a ZBEDl /SPEFl
complex binds to sedlin, the DUF 1042 domain may in part mediate this interaction.
Therefore, it would be of interest to test the involvement of the DUF 1042 domain in
binding to sedlin and in membrane traffic. In addition, TRAPP may have an as yet
unidentified specialized role in spermatogenesis. Using mouse SPATA4- and SPEFl -null
models, it would be of interest to observe the resulting phenotype and determine the
effect on TRAPP localization and assembly. If TRAPP and/or TRAPP isocomplexes do
play a specialized role in spermatogenesis then an observed defect in spermatogenesis in
the above null models is hypothesized to correspond with an affected localization and/or
assembly of TRAPP or TRAPP isocomplexes.
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4.4 Implications in Disease
The goal of this study was to begin to characterize sedlin by identifying its
interacting partners. In addition, the goal was also to use the obtained knowledge to gain
insight into how mutations in sedlin lead to the genetic skeletal disorder, SEDT. Using a
Y2H screen SPATA4 was discovered as a novel sedlin interactor and the interaction was
verified using various biochemical methods. Initially, the interaction between sedlin and
SPATA4 was not considered to have any relevance to SEDT since SEDT is a skeletal
disorder, and thus far, there have been no reports of any testis-related issues in SEDT
patients. However, further scrutiny of the interaction leads to some interesting links. It is
known that SEDT manifests in early childhood at -10-15 years of age, and it is also
known that that age range coincides with the age where sexual maturity commences.
Therefore, the manifestation of SEDT may be linked to the hormonal and/or chemical
changes that occur in individuals upon the commencement of sexual maturity, where the
latter has been linked to the expression levels of SPATA4. It is unknown how SPATA4
expression may influence the manifestation of SEDT. However given that both manifest
at around the same age interval suggests there might be a link since sedlin interacts with
SPATA4 and mutations in sedlin lead to SEDT. One documented missense mutation in
sedlin is D47Y. It has been suggested that since the D47Y residue is exposed on the
surface of sedlin that perhaps the mutation prevents sedlin from forming productive
interactions; which therefore leads to SEDT (Jang et al., 2002b). However, Y2H showed
that the SPATA4-sedlin interaction was not affected by the D47Y mutation. It is possible
that the ?2? system is not sensitive enough to pick up the difference in binding between
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the sedlin D47Y mutant with SPATA4. To determine if there is a difference in binding
strengths a more sensitive approach such as surface plasmon resonance (SPR) can be
performed. Furthermore, if SPATA4 is linked to SEDT then perhaps there are one or
more unobserved phenotypes in SEDT patients related to spermatogenesis or gonad
development. One way to check this would be to test the expression level of SPATA4 in
the testis and/or gonad of SEDT patients. As this is the first study to propose that
SPATA4 is linked to SEDT, it is clear that further work remains to be done to
characterize the relationship and dynamics between sedlin, SPATA4 and SEDT.
4.5. Future Perspectives
This study has shown a novel interaction between SPATA4 with a high molecular
weight TRAPP complex. Furthermore, this interaction was found to be mediated through
a physical interaction between sedlin and SPATA4 and suggests a link between SPATA4
and membrane traffic. A bioinformatic analysis of SPATA4 reveals the presence of a
DUF 1042 domain and also reveals another potential sedlin-interactor called SPEFl.
SPEFl is one of only three known human proteins to contain the DUF 1042 domain, and
may interact with sedlin via the formation of a heterodimeric complex containing
SPEFl /ZBEDl. If SPEFl does indeed interact with sedlin then this interaction may
provide the link that ties together vesicle tethering to Golgi-mediated traffic via the
microtubules (Presley et al., 1997), since there is evidence that suggests an interaction
between SPEFl and microtubules via a CH domain (Dougherty et al., 2005).
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Furthermore, both sedlin and SPEFl are broadly expressed (Genecards) which may
further support an interaction between the two proteins. As this is the first study to
propose a link between vesicle tethering and Golgi-mediated trafficking via
mictrotubules, further work remains to illuminate the mechanisms and intricacies of the
relationship between the two transport pathways. It is certain that any insight gained will
be transferable to similar cellular events and that such knowledge will increase the
current understanding and knowledge of cross-talk and transport events within the cell.
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